A researcher has found a reliable way to diagnose equine protozoal myeloencephalitis (EPM) in the acutely affected horse by examining genetic markers in its blood. This technique could potentially be applied to detect evidence of other infectiou
Although progress has been made studying equine protozoal myeloencephalitis (EPM) in the last 10 years, some aspects of the disease remain elusive. One researcher, half-jokingly, notes that EPM is considered the most diagnosed neurologic disorde
Programs that use no rotation involve the continued use of one effective drug until it no longer reduces small strongyle numbers as indicated by fecal egg counts.
“Equine protozoal myeloencephalitis (EPM) is a common cause of neurological disease of horses in North and South America, and results from a protozoal infection with Sarcocystis neurona or Neospora hughesi (less commonly),” said
“I think every time we find out something about EPM (equine protozoal myeloencephalitis), it turns up more questions,” said Bill Saville, DVM, PhD, Dipl. ACVIM, an associate professor in the Department of Veterinary Preventive Medicine at The
“Equine protozoal myeloencephalitis (EPM) is a common cause of neurological disease of horses in North and South America, and results from a protozoal infection with Sarcocystis neurona or Neospora hughesi (less commonly),”
Dynamic discussions about future equine protozoal myeloencephalitis (EPM) diagnostic methods and current EPM treatments were sparked at a June 11 meeting of the Equine Protozoal Myeloencephalitis Society (EPMS) in Minneapolis, Minn. The event,
(Revised 12/5/03) Horse owners have a new option for treating equine protozoal myeloencephalitis (EPM) following the Nov. 19 U.S. Food and Drug Administration’s (FDA) approval of nitazoxanide. This medication has been under development
The day before the scientific sessions started during the AAEP Convention, there was a series of forums and committee meetings. These were moderated by selected experts in those fields, and were open to anyone for a majority of the time. The las
Researchers recently identified the sea otter as a natural intermediate host for Sarcocystis neurona, the one-celled protozoan parasite that causes equine protozoal Myeloencephalitis (EPM). Muscle from a naturally-infected sea otter use
From Equine Disease Quarterly, Funded by Underwriters at Lloyd’s, London, Brokers, and Their Kentucky Agents,
Horse owners worried about equine protozoal myeloencephalitis (EPM) take note: In the next few months, there could be several new products reaching the market designed to treat or prevent this neurological disease caused by a single-celled
On Dec. 18, 2000, a vaccine to prevent EPM was approved by the USDA. As of Jan. 25, a total of 43 states had approved the use of the EPM vaccine under USDA conditional licensure. The vaccine must be used under the supervision of a
The Food and Drug Administration (FDA) has approved the first drug to treat equine protozoal myeloencephalitis (EPM) in horses. Bayer Animal Health of Shawnee Mission, Kan., is the sponsor of the drug ponazuril, which will have the trade name
More than 50 years ago, horses at The Jockey Club in San Paulo, Brazil, were suffering from a neurologic disease that caused muscle wasting. In 1964, that same disease was seen in North America. Robert MacKay, BVSc, PhD, Dipl. ACVIM, of the
Researchers have discovered that the striped skunk can serve as an intermediate host in the laboratory for Sarcocystis neurona, the single-celled protozoan parasite that causes equine protozoal myeloencephalitis (EPM). The striped skunk’s
Stay on top of the most recent Horse Health news with
